2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Immunotherapy, Artificial Intelligence (AI), Deep Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Diseases, Immunology, Neutropenia, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly
PAPER

3933 Characterization of p53-deficient multiple myeloma identifies potential therapeutic vulnerabilities

Nolan Thomas Tucker, PhD, Shannon Matulis, PhD2, Yurie Miyamoto, PhD3, Sanjana Prudhvi, PhD4, Yu Zhang, MPH5, Beena Elizabeth Thomas, PhD6, Jonathan Licht, MD7, Constantine Mitsiades, MD, PhD8, Jonathan Keats, PhD9, Vikas Gupta, MD, PhD10, Arun Wiita, MD, PhD11, Benjamin Gabriel Barwick, PhD12, Lawrence H Boise, PhD13
1 Emory School of Medicine and the Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
2 Emory School of Medicine and the Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
3 Emory School of Medicine and the Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
4 University of California, San Francisco, San Francisco, California, United States
5 Emory School of Medicine and the Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
6 Emory School of Medicine and the Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
7 University of Florida Health Cancer Center, Gainesville, Florida, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Translational Genomics Research Institute, Phoenix, Arizona, United States
10 Emory School of Medicine and the Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
11 University of California, San Francisco, San Francisco, California, United States
12 Emory School of Medicine and the Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
13 Emory School of Medicine and the Winship Cancer Institute, Emory University, Atlanta, Georgia, United States

Multiple myeloma (MM) is a malignancy of plasma cells that remains incurable. The gene TP53 encodes the p53 tumor suppressor protein that plays a critical role in many pathways central to proper cellular function including cell-cycle regulation, apoptosis, and DNA-damage response. Although TP53 mutations and deletions are relatively rare at diagnosis, making up only ~5% of newly diagnosed MM cases, they are associated with poor outcomes and a marker of high-risk disease. Additionally, they become more frequent with disease progression. Despite the clinical importance of TP53 loss, its molecular consequences in MM remain insufficiently characterized. Therefore, we set out to characterize the molecular landscape of TP53 loss using isogenic cell models with the goal of revealing novel therapeutic vulnerabilities associated with p53 loss for targeting in this high-risk patient population.  

To systematically test the consequences of TP53 loss, we generated p53-deficient derivatives of the p53-wildtype MM cell lines, NCI-H929 (H929) and MM.1S. Loss-of p53 protein was validated by Western blot and functional analysis. Edited H929 and MM.1S cells acquired resistance to the MDM2 inhibitor, Nutlin-3a (p=0.0050 and p=0.019, respectively). Nutlin-3a activates p53-mediated apoptosis by disrupting the MDM2-p53 interaction, confirming loss of functional p53 signaling. We also conducted pharmacologic screens that identified increased resistance of p53-deficient H929 cells, but not p53-deficient MM.1S cells, to the MCL1 inhibitor, AZD5991 (p=0.0095 and p=0.65, respectively), and to melphalan (p=0.038 and p=0.23, respectively). In contrast, loss-of TP53 had no effect on the response to bortezomib in either cell line. These findings suggest that H929 cells have a measurable TP53 response while in MM.1S, the response was only observed when MDM2 was inhibited.

To further characterize these responses, we performed RNAseq to determine the transcriptional changes associated with loss-of TP53 in these isogenic models. In H929 we identified 73 differentially expressed genes (DEGs: TP53, 62 downregulated and 10 upregulated), including canonical p53-target genes including MDM2, CDKN1A (p21) and TNFRSF10B. Interestingly, we also observed changes in myeloma-related genes not typically associated with p53. These include increased expression of FGFR3, a gene translocated in t(4;14) myeloma like H929, as well as the immunotherapy target, FCRL5. In contrast, in MM.1S cells, we identified only 3 significant DEGs, including TP53 and the known p53 target, RPS27L, while MDM2, CDKN1A, and TNFRSF10B, did not reach significance. One lncRNA that has not been previously linked to p53 was also found to be upregulated.

Despite expressing wild-type p53, MM.1S phenotypically, and transcriptionally, resembled a cell with at least a partial loss-of p53 function. These cells have a homozygous deletion of CDKN2A which encodes the MDM2 inhibitor p14 ARF that does not exist in the sister MM.1R cell line. We determined that these cells lack p14 ARF expression and taken together with the loss of sensitivity to Nutlin-3a are consistent with unchecked MDM2 activity resulting in a loss-of p53 function.

These findings also suggest that the p53-deficient H929 cell line provides a robust model for investigating the downstream consequences of p53 deficiency. To further define molecular changes associated with p53 loss, we performed cell-surface proteomic profiling of p53-deficient and p53-wildtype H929 cells and identified 91 differentially expressed proteins including an increase in surface expression of FGFR3 and GPRC5D and a decrease in FAS in the p53-deficient cells. We have validated FGFR3 changes by flow cytometry and will provide data on the functional consequences of changes to GPRC5D and FAS.   

Our data demonstrate that TP53 loss is associated with drug resistance and expression of well characterized p53-regulated genes that control cell growth and survival in MM.  However, we have also identified genes that have not been previously associated with p53 responses and could have important implications for therapeutic approaches, particularly for immune-based therapy. Additionally, we demonstrate that alterations upstream of p53 can render wild-type p53 functionally inert.  While loss-of CDKN2A and gain-of MDM2 are not common events, they could have the same impact as TP53 mutation or loss and therefore may contribute to functional high-risk myeloma.

Nolan Thomas Tucker, PhD: No relevant conflicts of interest to declare.